Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 441 - 460 results of 115,601 for search '(( 5 a decrease ) OR ( 10 ((ng decrease) OR (((we decrease) OR (mean decrease)))) ))', query time: 0.96s Refine Results
  1. 441
    Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome.

    Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome. by Jennifer Gribble (10005444)

    Published 2021
    Save to List
    Saved in:
  2. 442
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 443
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 444
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 445
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 446
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 447
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 448
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 449
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 450
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 451
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 452
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 453
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 454
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 455
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 456
    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each combination of drill system (MIPS and MONO) and drilling protocol (DP1-DP5).

    Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... by Marsel Ganeyev (21453399)

    Published 2025
    Save to List
    Saved in:
  17. 457
    Reducing Dscam1 diversity decreases adult lifespan in an exon-specific manner, Related to Fig 3.

    Reducing Dscam1 diversity decreases adult lifespan in an exon-specific manner, Related to Fig 3. by Haiyang Dong (4783608)

    Published 2025
    Save to List
    Saved in:
  18. 458
    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX

    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

    Published 2022
    “…</p><p>Conclusion:CLEC16A variants conferred a decreased risk to AR in the Chinese population.…”
    Save to List
    Saved in:
  19. 459
    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX

    Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

    Published 2022
    “…</p><p>Conclusion:CLEC16A variants conferred a decreased risk to AR in the Chinese population.…”
    Save to List
    Saved in:
  20. 460
    Comparison of glucose consumption and lactate production in culture medium of HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment.

    Comparison of glucose consumption and lactate production in culture medium of HL-1 cells exposed to LG, NG, HG and IHG between short- (12h) and long-time (72h) glucose treatment. by Patrick Mordel (17020879)

    Published 2023
    Save to List
    Saved in:

Search Tools: